Skip to main content
SGHT logo

SGHT · Sight Sciences, Inc. · Financials

Track SGHT — free
$10.08 +0.32 (+3.28%) At close · Nov 6 Play latest call Q2 2026 earnings call transcript
Market Cap
$555.51M
Shares
55.58M
Volume · Nov 6 576.41K Avg daily vol (3M) 300.98K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$77.36M -3.1%
FY2025 Revenue FY2020–FY2025
Net Income
-$38.43M +25.4%
FY2025 Net Income FY2020–FY2025
Gross Margin
86.17% +0.7pp
FY2025 Gross Margin FY2020–FY2025
Operating Margin
-47.95% +15.3pp
FY2025 Operating Margin FY2020–FY2025
Diluted EPS
-$0.74 +28.2%
FY2025 Diluted EPS FY2021–FY2025
Operating Cash Flow
-$29.69M -32.9%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
$88M – $92M $88.39M $77.36MG $79.87M $81.06MG $71.33MG $48.96MG $27.64M
— $10.83M $10.7M $11.58M $11.88M $12.36M $8.61M $9.21M
— $77.56M $66.67M $68.29M $69.18M $58.97M $40.35M $18.43M
— — 86.17% 85.5% 85.34% 82.67% 82.41% 66.68%
— $10.2M $14.61M $17.99M $17.56M $22.86M $15.63M $8.87M
— — — — — — — $1.8M
— $93.46M $89.16M $100.83M $108.89M $120.07M $76.19M $41.75M
— $415K $487K $712K $614K — — —
— $103.66M $103.77M $118.82M $126.45M $142.92M $91.82M $50.62M
— -$26.1M -$37.1M -$50.53M -$57.27M -$83.95M -$51.48M -$32.19M
— — -47.95% -63.27% -70.66% -117.7% -105.15% -116.45%
— -$25.68M -$36.61M -$49.82M -$56.66M — — —
— $5.16M $5.14M $4.66M $5.41M $4.47M $4.37M $2.4M
— — — — — — — $30K
— -$29K -$148K -$32K -$44K $2.23M -$6.93M -$71K
— -$28.34M -$38.42M -$51.27M -$55.44M -$86.2M -$62.77M -$34.63M
— $58K $10K $236K $110K $47K $188K $61K
— -$28.4M -$38.43M -$51.51M -$55.55M -$86.24M -$62.96M -$34.69M
— — -49.67% -64.49% -68.53% -120.9% -128.61% -125.52%
USD/shares — -$0.51 -$0.74 -$1.03 -$1.14 -$1.80 -$2.36 —
USD/shares — -$0.51 -$0.74 -$1.03 -$1.14 -$1.80 -$2.36 —
shares — — 52.15M 50.13M 48.63M 47.85M 26.73M 9.36M
shares — — 52.15M 50.13M 48.63M 47.85M 26.73M 9.36M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Debt Profile

Completed filing coverage through Dec 11, 2024

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current operating lease liabilities 2026-09-30 USD 399,000 10-Q filed 2026-11-04
Long-term debt, including current maturities 2026-09-30 USD 42,380,000 10-Q filed 2026-11-04
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current portion of long-term debt
USD 6,063,000
Noncurrent debt carrying amount
USD 34,966,000
Noncurrent operating lease liabilities 2026-09-30 USD 678,000 10-Q filed 2026-11-04
Short-term borrowings 2026-09-30 USD 6,063,000 10-Q filed 2026-11-04
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

Tranche 1(b) Term Loan Advance

TermLoan · Sight Sciences, Inc.

Reference: Tranche 1(b) Term Loan Advance

Active
Original principal
USD 5,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2024-12-10 Original principal USD 5,000,000 Exact source document Parent 8-K filing · 2024-12-11
    On December 10, 2024 (the “Closing Date”), Sight Sciences, Inc. (the “Company”) consummated the drawdown of the $5.0 million Tranche 1(b) Term Loan Advance (the “Tranche Loan”) contemplated by that certain Loan and Security Agreement (the “Loan Agreement”) by and among the Company, Hercules Capital, Inc. (“Hercules”) and certain affiliates of Hercules (collectively with Hercules, the “Lenders”). The Loan Agreement provides for a senior secured term loan facility in the aggregate original principal amount of up to $65.0 million (the “Term Loan Facility”). Upon consummation of the Tranche Loan, the aggregate principal amount of borrowings under the Loan Agreement was $40.0 million.
    Issuer evidence: On December 10, 2024 (the “Closing Date”), Sight Sciences, Inc. (the “Company”) consummated the drawdown of the $5.0 million Tranche 1(b) Term Loan Advance (the “Tranche Loan”) contemplated by that certain Loan and Security Agreement (the “Loan Agreement”) by and among the Company, Hercules Capital, Inc. (“Hercules”) and certain affiliates of Hercules (collectively with Hercules, the “Lenders”). The Loan Agreement provides for a senior secured term loan facility in the aggregate original principal amount of up to $65.0 million (the “Term Loan Facility”). Upon consummation of the Tranche Loan, the aggregate principal amount of borrowings under the Loan Agreement was $40.0 million.
    Supporting evidence: On December 10, 2024 (the “Closing Date”), Sight Sciences, Inc. (the “Company”) consummated the drawdown of the $5.0 million Tranche 1(b) Term Loan Advance (the “Tranche Loan”) contemplated by that certain Loan and Security Agreement (the “Loan Agreement”) by and among the Company, Hercules Capital, Inc. (“Hercules”) and certain affiliates of Hercules (collectively with Hercules, the “Lenders”). The Loan Agreement provides for a senior secured term loan facility in the aggregate original principal amount of up to $65.0 million (the “Term Loan Facility”). Upon consummation of the Tranche Loan, the aggregate principal amount of borrowings under the Loan Agreement was $40.0 million.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
5.87×
Peer median 2.85×
EV/EBIT
—
Peer median 22.97×
P/E (TTM)
—
Peer median 25.52×
Price/Sales (TTM)
6.28×
Peer median 3.14×
Price/Book
11.31×
Peer median 3.31×

Peer medians compare against the 73 similar-size Medical Devices companies (of 162 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Surgical Glaucoma $75,724,000 $75,902,000 $74,310,000 $65,594,000 $46,496,000 $26,000,000
Dry Eye $1,639,000 $3,964,000 $6,746,000 $5,737,000 $2,460,000 $1,640,000
Key facts CIK 1531177 CUSIP 82657M105 13F (30d) 50 filings 38 filers Visit website Investor relations